Manufacturers' association says pharma contract manufacturing in India growing at 20%

The Indian Drug Manufacturers' Association (IDMA) says the country's pharmaceutical contract manufacturing industry is growing at 20%. The group says current market value of the industry is an estimated 50% of domestic production, which is the equivalent of $5.3 billion. Multinationals control between 20% to 25% of the domestic pharmaceutical market. The IDMA says the Indian government is looking to put more incentives into upgrading Schedule M facilities. Article

Suggested Articles

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.

Celltrion remains optimistic it will get U.S. approval for its two biosimilar drugs, Rituxan and Herceptin, by the end of the year.